![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Efficacy and Safety of Dolutegravir/Lamivudine (DTG/3TC) in Black and Asian Participants From TANGO and SALSA: Pooled 48-Week Data Analyzed by Race
|
|
|
Glasgow 2022 Oct 23-26
Princy Kumar,1 Debbie Hagins,2 Jaime Federico Andrade-Villanueva,3 Po-Liang Lu,4 Eisuke Adachi,5 Rafael Rubio,6 Thomas Lutz,7 Mounir Ait-Khaled,8 Richard Grove,9 Brian Wynne,10 Bryn Jones,8 Chinyere Okoli8
1Georgetown University Medical Center, Washington, DC, USA; 2Georgia Department of Public Health, Coastal Health District, Chatham CARE Center, Savannah, GA, USA; 3Hospital Civil "Fray Antonio Alcalde," Guadalajara, Mexico; 4Kaohsiung Medical University, Kaohsiung, Taiwan; 5University of Tokyo, Tokyo, Japan; 6Hospital Universitario 12 de Octubre, UCM, Madrid, Spain; 7Infektiologikum, Frankfurt, Germany; 8ViiV Healthcare, Brentford, UK; 9GSK, Brentford, UK; 10ViiV Healthcare, Durham, NC, USA
![1117221](../images/111722/111722-19/1117221.gif)
![1117222](../images/111722/111722-19/1117222.gif)
![1117223](../images/111722/111722-19/1117223.gif)
![1117224](../images/111722/111722-19/1117224.gif)
![1117225](../images/111722/111722-19/1117225.gif)
![1117226](../images/111722/111722-19/1117226.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|